Kanda Holdings Co.,Ltd. Logo
JP3229980002

Kanda Holdings Co.,Ltd.

Ins Portfolio

Kurse werden geladen...

 Anzeige

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program

    MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program

    GHENT, Belgium--(BUSINESS WIRE)--MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets. With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases to the clinical development stage. IFF joined forces with microbiome specialist MRM Health in 2020, aiming to tackle a range of metabolic diseases. In this research, the proprietary MRM Health CORAL® technology platform and some selected IFF strains will be combined to develop novel therapeutics based on live bacterial strain combinations. “We are very pleased to see the progress that MRM Health and IFF have made within our partnership programs in metabolic health,” said Oliver Hasselwander, technical fellow, IFF. “By reaching this preclinical milestone in the diabetes program, MRM Health has further demonstrated that their technology platform is unique in identifying next generation microbiome solutions, and we look forward to developing these together with MRM Health.” The gut microbiome has a recognized role in non-alcoholic fatty liver disease (NAFLD) and associated diseases such as Type-2 diabetes and obesity. The two companies will continue the NAFLD program to further build on promising lead consortia. IFF and MRM Health’s collaboration on NAFLD will enable both parties to build upon the preclinical results, showing that a nine-strain bacterial consortium delays NAFLD progression and liver fibrosis. Part of this work was recently published in Biomedicines. "This second milestone achievement is an important step in demonstrating our team's expertise and the capacity of our unique CORAL® platform to deliver differentiated microbiome therapeutics across different diseases,” said Sam Possemiers, CEO and co-founder of MRM Health. “We are delighted to be working with IFF to rapidly drive the program through this preclinical phase, and we are confident that our technologies have the potential to deliver future life-changing oral therapeutics for patients." MRM Health’s CORAL® platform utilizes a bioinformatics-guided in-human discovery engine, combined with a breakthrough in optimization and manufacturing of consortia as single drug substance. The proprietary consortia optimization technology allows for the development of next-generation consortia therapeutics with faster onset-of-action and increased potency and robustness. The breakthrough scalable, robust, and standardized cGMP-compliant consortia manufacturing technology allows to manufacture complete therapeutic consortia as a single drug substance in a single manufacturing process which strongly surpasses existing approaches in speed, reduced complexity, increased robustness and lower cost. About MRM Health MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome. The company has built a diversified pipeline with its proprietary CORAL® platform to design, optimize, and manufacture bacterial consortia as single drug substance. Its most advanced program MH002 is an optimized consortium of 6 rationally-selected and well-characterized commensal strains. MH002 is currently being studied in two Phase 2 studies in patients with mild-to-moderate Ulcerative Colitis and acute Pouchitis, respectively. Additional pipeline development includes a preclinical program in Parkinson’s disease, preclinical programs in Type 2 Diabetes and in NAFLD (both partnered with IFF, previously DuPont), and a discovery program in autoimmune disease, including spondyloarthritis. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. ** END**» Mehr auf businesswire.com

  • Foto von ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects

    ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects

    TOULOUSE, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today the publication in Biomedecines of the first clinical data demonstrating that CER-001 limits inflammation effects in acute inflammatory conditions such as COVID-19. COVID-19 is associated with respiratory symptoms characterized by acute lung injury, rapidly progressing to acute respiratory distress syndrome. The pulmonary dysfunction is rapidly accompanied by a major "cytokine storm" in which inflammatory cytokines are abundantly released into the bloodstream leading to host tissue damage. Decreased levels of total cholesterol, LDL and HDL have been observed in patients with COVID-19 infections. Patients with low HDL levels at hospital admission have an increased risk of developing severe disease compared with patients with high HDL levels. With recovery from COVID-19 infections, serum lipid levels return to pre-infection levels High-density lipoproteins (HDL) in addition to their reverse cholesterol transport function, exhibit pleiotropic properties, including antiinflammatory, anti-apoptotic, anti-thrombotic, and antioxidant functions. CER-001 is an HDL mimetic previously tested in various pathological conditions, but never in COVID-19 before a compassionate access authorization (CAA) granted by the ANSM for bio-HDL (CER-001) in COVID-19 in January 2021. The Biomedecines publication reports on the first clinical administration of recombinant HDL particles, CER-001, in a patient with severe COVID-19 infection in an intensive care unit. Shotgun proteomics were performed on HDL before and after CER-001 infusions and serve to identify the type of proteins contained in HDL. These analyses demonstrated that apoA-I increased after injections while most pro-inflammatory proteins decreased following injections. Measurement of serum amyloid A-1, inflammatory markers, and cytokines showed a significant decrease in most of them during CER-001 treatment. The results suggest recombinant HDL infusions are a potential therapeutic strategy to be explored in COVID-19 patients. The publication shows for the first time that intravenous HDL supplementation (through CER-001 infusion for instance) is feasible in acute inflammatory conditions such as COVID-19, with a tendency to limit inflammation. HDLs have been shown to reduce inflammation in models of bacterial sepsis in part via their ability to bind and remove circulating endotoxins. However, in viral sepsis, HDL infusion may be also beneficial, particularly by reducing inflammationvia a still unknown mechanism. . This case report encourages the conduct of a randomized placebo-controlled trial to evaluate the contribution of rHDL in severe ICU COVID-19 patients. This scientific publication, entitled "First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploriatory Investigation," is available online in the journal Biomedecines: https://www.mdpi.com/2227-9059/10/4/754/htm ABIONYX Pharma is awaiting further results from ongoing clinical studies in inflammatory conditions. Next financial press release: Annual Results, April 28th 2022 About ABIONYX Pharma ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.» Mehr auf businesswire.com

  • Foto von ABIONYX Pharma annonce des résultats cliniques positifs pour CER-001 dans le traitement de la COVID-19, publiés dans la revue Biomedecines, démontrant que CER-001 limite les effets de l’inflammation

    ABIONYX Pharma annonce des résultats cliniques positifs pour CER-001 dans le traitement de la COVID-19, publiés dans la revue Biomedecines, démontrant que CER-001 limite les effets de l’inflammation

    TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME) (Paris:ABNX), société biotech de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes, annonce aujourd’hui la publication dans la revue Biomedecines de premières données cliniques démontrant que CER-001 limite les effets de l’inflammation dans le cas de conditions inflammatoires aiguës telles que la COVID-19. La COVID-19 est associée à des symptômes respiratoires caractérisés par une lésion pulmonaire aiguë, et évoluant rapidement vers un syndrome de détresse respiratoire aiguë. Le dysfonctionnement pulmonaire est rapidement accompagné d'un important « orage de cytokines » au cours duquel des cytokines inflammatoires sont abondamment libérées dans le sang entraînant des lésions des tissus de l'hôte. Il a été observé une diminution des taux de cholestérol total, de LDL et de HDL chez les patients atteints d'infections COVID-19. Les patients présentant un faible taux de HDL à l'admission à l'hôpital avaient un risque accru de développer une maladie grave par rapport aux patients présentant un taux de HDL élevé. Avec la guérison des infections COVID-19, les taux de lipides sériques reviennent aux niveaux présents avant l'infection. Les lipoprotéines de haute densité (HDL), en plus de leur fonction de transport inverse du cholestérol, présentent des propriétés pléiotropiques, notamment des fonctions anti-inflammatoires, anti-apoptotiques, anti-thrombotiques et antioxydantes. CER-001 est un mimétique des HDL préalablement testé dans différentes conditions pathologiques, mais jamais dans la COVID-19 avant une autorisation d'accès compassionnel (AAC) telle qu’elle avait pu être accordée par l’ANSM pour la bio-HDL (CER-001) dans la COVID-19 en janvier 2021. La publication de Biomedecines porte sur l’étude de la première administration clinique de particules HDL recombinantes, CER-001, chez un patient souffrant d'une grave infection à la COVID-19 et placé dans une unité de soins intensifs. L’analyse protéomique a été réalisée sur les HDL avant et après les perfusions de CER-001 et sert à identifier le type de protéines contenues dans les HDL. Ces analyses ont démontré que l'apoA-I augmente après les injections, alors que la plupart des protéines pro-inflammatoires diminuent après les injections. La mesure du sérum amyloïde A-1, des marqueurs inflammatoires et des cytokines a montré une diminution significative pour la plupart d'entre eux au cours du traitement par CER-001. Les résultats suggèrent que les perfusions de HDL recombinante constituent une stratégie thérapeutique potentielle à explorer chez les patients atteints de la COVID-19. La publication dans Biomedecines centrée sur un premier cas clinique montre pour la première fois que la supplémentation intraveineuse en HDL (par perfusion de CER-001 par exemple) est réalisable dans des conditions inflammatoires aiguës telles que la COVID-19, avec une tendance à limiter l'inflammation. Il a été démontré que les HDL réduisent l’inflammation dans les modèles de sepsis bactérien, en partie grâce à leur capacité à lier et à éliminer les endotoxines circulantes. Cependant, dans le cas d'une septicémie virale, la perfusion de HDL pourrait également être bénéfique, notamment en réduisant l'inflammation par un mécanisme encore inconnu. Ce rapport de cas est encourageant pour la réalisation d’un essai randomisé contre placebo visant à évaluer l'apport des bio-HDL, CER-001, chez les patients sévèrement atteints de COVID-19 en soins intensifs. Cette publication scientifique, intitulée « First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation », est disponible en ligne dans la revue Biomedecines : https://www.mdpi.com/2227-9059/10/4/754/htm ABIONYX Pharma reste dans l’attente de nouveaux résultats d’études cliniques en cours portant sur les maladies inflammatoires. Prochain communiqué financier : Résultats annuels, le 28 avril 2022 A propos d’ABIONYX Pharma ABIONYX Pharma est une société biotech de nouvelle génération qui entend contribuer à la santé grâce à des thérapies innovantes dans des indications sans traitement efficace ou existant, même les plus rares. Grâce à ses partenaires chercheurs, médecins, producteurs de biomédicaments et actionnaires, la société innove quotidiennement pour proposer des médicaments pour le traitement des maladies rénales et ophtalmologiques, ou de nouveaux vecteurs HDL utilisés pour la délivrance ciblée de médicaments.» Mehr auf businesswire.com

Dividenden

Alle Kennzahlen
In 2024 hat Kanda Holdings Co.,Ltd. +0,12 Dividende ausgeschüttet. Die letzte Dividende wurde im Dezember 2024 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Kanda Holdings Co.,Ltd. einen Umsatz von +82,36 Mio und ein Nettoeinkommen von +3,62 Mio
(EUR)Sep. 2024
YOY
Umsatz+82,36 Mio2,85%
Bruttoeinkommen+8,91 Mio3,23%
Nettoeinkommen+3,62 Mio1,87%
EBITDA+5,30 Mio34,87%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+105,27 Mio
Anzahl Aktien
21,43 Mio
52 Wochen-Hoch/Tief
+5,60 - +4,00
Dividendenrendite
+2,48%
Dividenden TTM
+0,12
Beta
0,27
KGV (PE Ratio)
+7,44
KGWV (PEG Ratio)
42,30
KBV (PB Ratio)
+0,69
KUV (PS Ratio)
+0,33

Unternehmensprofil

Name
Kanda Holdings Co.,Ltd.
CEO
Fujihisa Harashima
Mitarbeiter2.784
🍪

Parqet nutzt Cookies.Erfahre Mehr